GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Cost of Goods Sold

Kaken Pharmaceutical Co (TSE:4521) Cost of Goods Sold : 円33,505 Mil (TTM As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Cost of Goods Sold?

Kaken Pharmaceutical Co's cost of goods sold for the three months ended in Dec. 2023 was 円8,374 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was 円33,505 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kaken Pharmaceutical Co's Gross Margin % for the three months ended in Dec. 2023 was 54.77%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Kaken Pharmaceutical Co's Inventory Turnover for the three months ended in Dec. 2023 was 0.46.


Kaken Pharmaceutical Co Cost of Goods Sold Historical Data

The historical data trend for Kaken Pharmaceutical Co's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Cost of Goods Sold Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38,753.00 34,073.00 34,459.00 33,429.00 33,505.00

Kaken Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,418.00 8,094.00 8,357.00 8,374.00 8,680.00

Kaken Pharmaceutical Co Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円33,505 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaken Pharmaceutical Co  (TSE:4521) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kaken Pharmaceutical Co's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(18514 - 8374) / 18514
=54.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Kaken Pharmaceutical Co's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Kaken Pharmaceutical Co Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines